



Press release

Jordbro, June 18th 2014

Recipharm and CTC forms new collaboration

CTC Clinical Trial Consultants AB, based in Uppsala, and Recipharm Pharmaceutical Development AB, based in Solna, Stockholm, are pleased to announce that they have entered into a collaboration.

Together the two companies will offer a complete set of packages for Phase I studies including development and manufacture of clinical trial material. The scope will cover planning, performing and evaluation of the clinical trial.

Maria Lundberg, General Manager Recipharm Pharmaceutical Development AB commented: "I am delighted about this collaboration. CTC has excellent experience in clinical trials and a unique phase I unit at Uppsala University Hospital (Akademiska Sjukhuset). Together we will be able to offer customers faster and more cost-efficient phase I studies. We can from now on take full responsibility for coordination of the work which might be valuable to small virtual companies"

Bengt Dahlström, CEO of CTC Clinical Trial said "I am very pleased that CTC and Recipharm now can offer a joint service which will benefit from the companies longstanding expertise in contract development and manufacturing and early clinical research. This systematic integrated approach will help our clients to shorten project time-lines and at the same time obtain more information on the desirable properties of the drug formulation. Adaptive design is a key element in getting more information from each study and modifying the design based on the data obtained all within a single protocol."

For more information contact:

Maria Lundberg, General Manager Recipharm Pharmaceutical Development AB
E-mail: maria.lundberg@recipharm.com, phone: +46 8 602 52 73

Bengt Dahlström, CEO CTC Clinical Trial Consultant AB
E-mail: bengt.dahlstrom@ctc-ab.se, phone: +46 703108587

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: t.jervis@defacto.com or a.heeley@defacto.com
Phone: +44 (0) 207 861 3019/3043

About Recipharm

Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry based in Sweden employing some 1,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and pharmaceutical product development. Recipharm currently manufactures more than 200 different products to both Big Pharma and smaller research- and development companies. Recipharm's turnover is approximately SEK 2.1 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered in Jordbro, Sverige. The Recipharm B-share (RECI B) is listed on Nasdaq OMX Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com.

Recipharm AB (publ)
Corporate identity number 556498-4825
Address Lagervägen 7, SE-136 50 Jordbro **Telephone** +46 8 602 52 00
Fax +46 8 81 87 03, www.recipharm.com



About CTC

CTC AB is a specialist CRO focused on the early clinical studies in translational medicine offering our clients in the pharmaceutical, CRO and medical technology sectors cost-effective conduct of hospital-based early clinical trials (phase 0/I/IIa). The company operates a dedicated 12-bed research clinic at the University Hospital in Uppsala, combined with two SMO-sites in Linköping and Uppsala, Sweden. The research unit is inspected and approved by the Medical Products Agency in Sweden, for the conduct of first-in-human studies.

www.clinicaltrialconsultants.se